Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Nov 2007:30 AM PST
-08:30 AM PST
Learn what truly sets the UC Riverside MBA apart and how it helps in your professional growth
Nov 2001:30 PM EST
-02:30 PM IST
Learn how Kamakshi achieved a GMAT 675 with an impressive 96th %ile in Data Insights. Discover the unique methods and exam strategies that helped her excel in DI along with other sections for a balanced and high score.
Nov 2206:30 AM PST
-08:30 AM PST
Let’s dive deep into advanced CR to ace GMAT Focus! Join this webinar to unlock the secrets to conquering Boldface and Paradox questions with expert insights and strategies. Elevate your skills and boost your GMAT Verbal Score now!
Nov 2211:00 AM IST
-01:00 PM IST
Do RC/MSR passages scare you? e-GMAT is conducting a masterclass to help you learn – Learn effective reading strategies Tackle difficult RC & MSR with confidence Excel in timed test environment- Nov 23
11:00 AM IST
-01:00 PM IST
Attend this free GMAT Algebra Webinar and learn how to master the most challenging Inequalities and Absolute Value problems with ease. 
Nov 2407:00 PM PST
-08:00 PM PST
Full-length FE mock with insightful analytics, weakness diagnosis, and video explanations!
Nov 2510:00 AM EST
-11:00 AM EST
Prefer video-based learning? The Target Test Prep OnDemand course is a one-of-a-kind video masterclass featuring 400 hours of lecture-style teaching by Scott Woodbury-Stewart, founder of Target Test Prep and one of the most accomplished GMAT instructors.
24 Aug 2024, 06:12
Kudos
Bookmarks
E
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
5%
(low)
Question Stats:
91% (01:30) correct
9%
(01:44)
wrong
based on 164
sessions
History
Date
Time
Result
Not Attempted Yet
Clinician: Patients with immune system disorders are usually treated with a class of drugs that, unfortunately, increase the patient's risk of developing osteoporosis, a bone-loss disease. So these patients take another drug that helps to preserve existing bone. Since a drug that enhances the growth of new bone cells has now become available, these patients should take this new drug in addition to the drug that helps to preserve existing bone.
Which one of the following would be most useful to know in order to evaluate the clinician's argument?
(A) How large is the class of drugs that increase the risk of developing osteoporosis?
(B) Why are immune system disorders treated with drugs that increase the risk of developing osteoporosis?
(C) Is the new drug more expensive than the drug that helps to preserve existing bone?
(D) How long has the drug that helps to preserve existing bone been in use?
(E) To what extent does the new drug retain its efficacy when used in combination with the other drugs?
Which one of the following would be most useful to know in order to evaluate the clinician's argument?
(A) How large is the class of drugs that increase the risk of developing osteoporosis?
(B) Why are immune system disorders treated with drugs that increase the risk of developing osteoporosis?
(C) Is the new drug more expensive than the drug that helps to preserve existing bone?
(D) How long has the drug that helps to preserve existing bone been in use?
(E) To what extent does the new drug retain its efficacy when used in combination with the other drugs?
RishS94
Joined: 05 Jan 2020
Last visit: 27 Feb 2025
Posts: 266
Own Kudos:
Given Kudos: 118
Location: India
Concentration: Strategy, Sustainability
Schools: ISB '25 (D)
GMAT 1: 690 Q49 V35
GPA: 3.5
Products:
25 Aug 2024, 05:32
Kudos
Bookmarks
Drug X will stop OP.
Drug Y will aid bone growth.
So take X + Y.
Assumption X+Y won't interfere to reduce the loss.
Drug Y will aid bone growth.
So take X + Y.
Assumption X+Y won't interfere to reduce the loss.
25 Aug 2024, 20:50
Kudos
Bookmarks
Conclusion: Patients with immune system disorders should take the new drug that enhances the growth of new bone cells in addition to the existing drug that helps to preserve existing bone
Which one of the following would be most useful to know in order to evaluate the clinician's argument?
(A) How large is the class of drugs that increase the risk of developing osteoporosis?
NO. This might help in evaluating the existing drug usage, this wont help in Clinician's argument on taking the new drug.
(B) Why are immune system disorders treated with drugs that increase the risk of developing osteoporosis?
NO. This might be a unfortunate side effect of class of drugs for immune system disorders. This will not help in evaluating why the patients should take both new and existing drug for osteoporosis.
(C) Is the new drug more expensive than the drug that helps to preserve existing bone?
NO. Cost of the drugs has no bearing in a suggestion for drugs. Irrelevant.
(D) How long has the drug that helps to preserve existing bone been in use?
NO. It may be a new drug developed few months ago or being used for years. This doesnt help in finding why the new drug should be taken in addition.
(E) To what extent does the new drug retain its efficacy when used in combination with the other drugs?
YES. If the efficacy of the new drug drops down when it is combined with a drug that helps to preserve bone, then Clinician's argument or recommendation becomes weak.
Answer is E
Which one of the following would be most useful to know in order to evaluate the clinician's argument?
(A) How large is the class of drugs that increase the risk of developing osteoporosis?
NO. This might help in evaluating the existing drug usage, this wont help in Clinician's argument on taking the new drug.
(B) Why are immune system disorders treated with drugs that increase the risk of developing osteoporosis?
NO. This might be a unfortunate side effect of class of drugs for immune system disorders. This will not help in evaluating why the patients should take both new and existing drug for osteoporosis.
(C) Is the new drug more expensive than the drug that helps to preserve existing bone?
NO. Cost of the drugs has no bearing in a suggestion for drugs. Irrelevant.
(D) How long has the drug that helps to preserve existing bone been in use?
NO. It may be a new drug developed few months ago or being used for years. This doesnt help in finding why the new drug should be taken in addition.
(E) To what extent does the new drug retain its efficacy when used in combination with the other drugs?
YES. If the efficacy of the new drug drops down when it is combined with a drug that helps to preserve bone, then Clinician's argument or recommendation becomes weak.
Answer is E
